Drugs / BAT1706
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed | China (NMPA) | — | — | — | “The China NMPA accepted the Biologics License Application (BLA) for BAT1706 in June 2020.” beonemedicines.com ↗ |
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials · 1 met primary | ||||||
| Phase 1 | NCT05865574 | Jun → Sep 2023 | — | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1 | NCT03030430 | Mar 2016 → May 2017 | non-small cell lung carcinoma | Bio-Thera Solutions | Completed | Met primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT04948697 | Aug 2021 → Feb 2024 | hepatocellular carcinoma | BeiGene | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT04164199 | Dec 2019 → May 2026 | cancer | BeOne Medicines | Completed | No outcome recorded |
| Phase 3 | NCT03329911 | Oct 2017 → Nov 2019 | non-small cell lung carcinoma | Bio-Thera Solutions | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-08-24 | BeOne Medicines | Bio-Thera Solutions and BeiGene Announce License, Distribution, and Supply Agreement for Avastin® (Bevacizumab) Biosimilar BAT1706 in China beonemedicines.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAT1706 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04948697 ↗ |
| Route | Intravenous | “after a single intravenous (IV) infusion” PMID 31016568 ↗ Jun 2019 |